Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19)
A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Severe COVID-19 Patients
Sponsor: Beijing 302 Hospital
A PHASE2 clinical study on Corona Virus Disease 2019(COVID-19), this trial is completed. The trial is conducted by Beijing 302 Hospital and has accumulated 11 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Nov 2022 — Jan 2024 [monthly]
Completed PHASE2
-
Oct 2021 — Nov 2022 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
May 2020 — Jul 2020 [monthly]
Recruiting PHASE2
Phase: PHASE1_PHASE2 → PHASE2
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2020 — Apr 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing 302 Hospital
- Huoshenshan Hospital
- Maternal and Child Health Hospital of Hubei Province
- The General Hospital of Central Theater Command
- Vcanbio Cell and Gene Engineering Corp., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .